China is supposed to be in the scene of vaccine deficiencies and hard to support poor countries, even though the Sinopharm vaccine has been urgently approved by WHO.

The World Health Organization (WHO) on May 7, the Covid-19 Vaccine statement produced by China's Sinopharm company to help anti-virus safely and reliably.

WHO Approving Vaccine Sinopharm for emergency use means it is capable of being included in the Covax program, a global initiative to provide free vaccines to poor countries.

Medical staff transporting Vaccine lots of Sinopharm on April 8.

Rich countries are accumulating large amounts of vaccines.

"The addition of Sinopharm will help to increase the accessibility of the Covid-19 vaccine for countries who want to protect people and their health workers before the risk," said Dr. Mari Nangela Simão, Assistant General Director

Vaccine access can be further improved next week, when WHO is considering approving another vaccine produced by China's Sinovac company.

Andrea Taylor, Data Data Analyst at Duke Global Health Institute, calling the addition of Chinese vaccines to the Covax program is "the song changes the game".

"The current situation is quite desperate for countries with medium or low income, so all doses are worth mobilizing," Taylor said.

However, many people are skeptical about the ability of Chinese vaccine contributions to global vaccination efforts.

"This should have been a golden time for China to implement its vaccine diplomatic policy. The problem is, at the same time, China itself is also under shortage," Yanzhong Huang, high-level medical expert

China's vaccination campaign started quite slowly, partly prioritized by the government and people did not feel the vaccination was urgent.

Sinopharm and Sinovac are producing about 12 million doses of vaccines every day, only negligible higher than 10 million doses that China hopes to provide daily to meet the domestic goals.

The two companies will have to produce additional about 500 million doses of vaccines if they want to meet the needs of other countries, according to the entire from Bridge Consulting, the Consulting Company is based in Beijing.

Vaccine deficiency shows the complexity in implementing China's mass-vaccinated campaign while hugging hopes to implement an ambitious export program.

"The whole world is missing vaccines, demand is huge," said Sinovac Pearson Liu spokesman.

Vaccine Covid-19 barrels from China's Sinovac company at Villamor Air Force Base, Philippines, on February 28.

In order to minimize deficiencies, Chinese officials said those who have injected their heads can delay second to 8 weeks, or they can combine vaccination from different companies.

Vaccine China has been moved to more than 80 countries, but they face a large doubt, partly because the company has not announced the three-stage testing data for independent evaluation scientists

Last week, an advisory group for WHO announced this data.

Data from the advisory group showed that they "have a high level of trust" that Vaccine Sinopharm promotes the effect of preventing Covid-19 in adults, but "low trust levels" for people over 60 years old.

WHO said that Sinopharm did not gather more than 60 years of age participating in clinical trials, they could not estimate its effectiveness on this age group.

Data on the effectiveness of Chinese vaccines for NCOV strains around the world are also quite limited, but in general, they are inferior to the vaccine produced by Pfizer-Biontech or Moderna.

But with Chinese leaders, the vaccine is approved by WHO no different from a "Honoral Medal".

After India last month restricted the export of vaccines, Indonesia and the Philippines said they would turn to the help from China.

Indonesia announced that the vaccine lots reinforced from Sinovac after President Joko Widodo conference with the President of the episode.

It is unclear whether the approval from WHO will change the Beijing's approach in providing vaccines.

"They don't want to show their generous hearts under the United Nations brand," said J. Stephen Morrison, Director of the Global Health Policy Center at the International Research and Research Center (CSIS), received